Literature DB >> 32952396

Non-Targeted Metabolomic Analysis Reveals Serum Phospholipid Alterations in Patients with Early Stages of Diabetic Foot Ulcer.

Ignacio I Álvarez-Rodríguez1, Eduardo Castaño-Tostado2, David G García-Gutiérrez2, Rosalía Reynoso-Camacho2, Juana E Elton-Puente1, Alicia Barajas-Pozos3, Iza F Pérez-Ramírez2.   

Abstract

Diabetic foot ulcer (DFU) is a common complication of type 2 diabetes mellitus (T2DM) characterized by ulcer formation, which can lead to the amputation of lower extremities. However, the metabolic alterations related to this complication are not completely elucidated. Therefore, we carried out a metabolomic analysis of serum samples obtained from T2DM adult patients diagnosed with diabetic foot ulcer in a cross-sectional, observational, and comparative study. Eighty-four volunteers were classified into the following groups: without T2DM (control group, n = 30) and with T2DM and different stages of diabetic foot ulcer according to Wagner-Meggitt classification system: DFU G0 (n = 11), DFU G1 (n = 14), DFU G2 (n = 16), and DFU G3 (n = 13). The non-target metabolomic profile followed by chemometric analysis revealed that lysophosphatidylethanolamine (16:1) could be proposed as key metabolite related to the onset of diabetic foot ulcer; however, this phospholipid was not affected by diabetic foot ulcer progression. Therefore, further studies are necessary to validate these phospholipids as biomarker candidates for the early diagnosis of diabetic foot ulcer in T2DM patients.
© The Author(s) 2020.

Entities:  

Keywords:  Diabetic foot ulcer; mass spectrometry; metabolomic analysis; phospholipids; type 2 diabetes mellitus

Year:  2020        PMID: 32952396      PMCID: PMC7485163          DOI: 10.1177/1177271920954828

Source DB:  PubMed          Journal:  Biomark Insights        ISSN: 1177-2719


  23 in total

1.  Metabolomic profile related to cardiovascular disease in patients with type 2 diabetes mellitus: A pilot study.

Authors:  Beatriz García-Fontana; Sonia Morales-Santana; Caridad Díaz Navarro; Pedro Rozas-Moreno; Olga Genilloud; Francisca Vicente Pérez; José Pérez del Palacio; Mnuel Muñoz-Torres
Journal:  Talanta       Date:  2015-10-27       Impact factor: 6.057

2.  Comprehensive foot examination and risk assessment.

Authors:  Andrew J M Boulton; David G Armstrong; Stephen F Albert; Robert G Frykberg; Richard Hellman; M Sue Kirkman; Lawrence A Lavery; Joseph W LeMaster; Joseph L Mills; Michael J Mueller; Peter Sheehan; Dane K Wukich
Journal:  Endocr Pract       Date:  2008 Jul-Aug       Impact factor: 3.443

Review 3.  Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis .

Authors:  Pengzi Zhang; Jing Lu; Yali Jing; Sunyinyan Tang; Dalong Zhu; Yan Bi
Journal:  Ann Med       Date:  2016-11-03       Impact factor: 4.709

Review 4.  The diabetic foot.

Authors:  Jamal Ahmad
Journal:  Diabetes Metab Syndr       Date:  2015-04-27

5.  Prevalence of diabetic foot ulceration and associated risk factors: an old and still major public health problem in Khartoum, Sudan?

Authors:  Ahmed O Almobarak; Heitham Awadalla; Mugtaba Osman; Mohamed H Ahmed
Journal:  Ann Transl Med       Date:  2017-09

6.  Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting.

Authors:  Karsten Suhre; Christa Meisinger; Angela Döring; Elisabeth Altmaier; Petra Belcredi; Christian Gieger; David Chang; Michael V Milburn; Walter E Gall; Klaus M Weinberger; Hans-Werner Mewes; Martin Hrabé de Angelis; H-Erich Wichmann; Florian Kronenberg; Jerzy Adamski; Thomas Illig
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

7.  Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update).

Authors:  Nicolaas C Schaper; Jaap J van Netten; Jan Apelqvist; Sicco A Bus; Robert J Hinchliffe; Benjamin A Lipsky
Journal:  Diabetes Metab Res Rev       Date:  2020-03       Impact factor: 4.876

Review 8.  Uric acid in metabolic syndrome: From an innocent bystander to a central player.

Authors:  Mehmet Kanbay; Thomas Jensen; Yalcin Solak; Myphuong Le; Carlos Roncal-Jimenez; Chris Rivard; Miguel A Lanaspa; Takahiko Nakagawa; Richard J Johnson
Journal:  Eur J Intern Med       Date:  2015-12-15       Impact factor: 4.487

9.  Comorbidity in patients with diabetes mellitus: impact on medical health care utilization.

Authors:  Jeroen N Struijs; Caroline A Baan; Francois G Schellevis; Gert P Westert; Geertrudis A M van den Bos
Journal:  BMC Health Serv Res       Date:  2006-07-04       Impact factor: 2.655

10.  Procalcitonin levels and other biochemical parameters in patients with or without diabetic foot complications.

Authors:  Shatha Abdul Wadood Al-Shammaree; Banan Akram Abu-ALkaseem; Isam N Salman
Journal:  J Res Med Sci       Date:  2017-08-16       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.